GSK, Sanofi jab shows promise in phase 2 trial

Monday, 17. May 2021 07:39

A COVID-19 vaccine developed by Sanofi S.A. and GlaxoSmithKline plc showed a strong immune response in all adult age groups in the second phase of the jab trial, the two companies announced on Monday.

According to the study, the sample of which counted 722 participants, the jab showed no safety concerns across all age groups. The trial also hinted that the companies' "adjuvanted recombinant COVID-19 vaccine candidate" could be used successfully as a booster shot for people who have already recovered from the infection. The third phase of the trial is expected to begin in the coming weeks, the announcement read.

"Our Phase 2 data confirm the potential of this vaccine to play a role in addressing this ongoing global public health crisis, as we know multiple vaccines will be needed, especially as variants continue to emerge and the need for effective and booster vaccines, which can be stored at normal temperatures, increases," Sanofi CEO Thomas Triomphe said.

Related Links: Sanofi S.A.GlaxoSmithKline PLC
Author:
Breaking the News / BU